These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
26. Opioid addicted buprenorphine injectors: drug use during and after 12-weeks of buprenorphine-naloxone or methadone in the Republic of Georgia. Piralishvili G; Otiashvili D; Sikharulidze Z; Kamkamidze G; Poole S; Woody GE J Subst Abuse Treat; 2015 Mar; 50():32-7. PubMed ID: 25456093 [TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of emergency department-initiated treatment for opioid dependence. Busch SH; Fiellin DA; Chawarski MC; Owens PH; Pantalon MV; Hawk K; Bernstein SL; O'Connor PG; D'Onofrio G Addiction; 2017 Nov; 112(11):2002-2010. PubMed ID: 28815789 [TBL] [Abstract][Full Text] [Related]
28. Characterizing opioid withdrawal during double-blind buprenorphine detoxification. Dunn KE; Saulsgiver KA; Miller ME; Nuzzo PA; Sigmon SC Drug Alcohol Depend; 2015 Jun; 151():47-55. PubMed ID: 25823907 [TBL] [Abstract][Full Text] [Related]
29. Comparison of behavioral treatment conditions in buprenorphine maintenance. Ling W; Hillhouse M; Ang A; Jenkins J; Fahey J Addiction; 2013 Oct; 108(10):1788-98. PubMed ID: 23734858 [TBL] [Abstract][Full Text] [Related]
30. Participant characteristics and buprenorphine dose. Hillhouse M; Canamar CP; Doraimani G; Thomas C; Hasson A; Ling W Am J Drug Alcohol Abuse; 2011 Sep; 37(5):453-9. PubMed ID: 21854290 [TBL] [Abstract][Full Text] [Related]
31. A preliminary randomized controlled trial of a distress tolerance treatment for opioid dependent persons initiating buprenorphine. Stein MD; Herman DS; Moitra E; Hecht J; Lopez R; Anderson BJ; Brown RA Drug Alcohol Depend; 2015 Feb; 147():243-50. PubMed ID: 25510307 [TBL] [Abstract][Full Text] [Related]
32. Effects of Buprenorphine Dose and Therapeutic Engagement on Illicit Opiate Use in Opioid Use Disorder Treatment Trials. Bergen AW; Baurley JW; Ervin CM; McMahan CS; Bible J; Stafford RS; Mudumbai SC; Saxon AJ Int J Environ Res Public Health; 2022 Mar; 19(7):. PubMed ID: 35409790 [TBL] [Abstract][Full Text] [Related]
33. A comparison between low-magnitude voucher and buprenorphine medication contingencies in promoting abstinence from opioids and cocaine. Gross A; Marsch LA; Badger GJ; Bickel WK Exp Clin Psychopharmacol; 2006 May; 14(2):148-56. PubMed ID: 16756418 [TBL] [Abstract][Full Text] [Related]
34. Buprenorphine in the emergency department: Randomized clinical controlled trial of clonidine versus buprenorphine for the treatment of opioid withdrawal. Srivastava A; Kahan M; Njoroge I; Sommer LZ Can Fam Physician; 2019 May; 65(5):e214-e220. PubMed ID: 31088887 [TBL] [Abstract][Full Text] [Related]
35. Impact of Current Pain Status on Low-Barrier Buprenorphine Treatment Response Among Patients with Opioid Use Disorder. Peck KR; Ochalek TA; Streck JM; Badger GJ; Sigmon SC Pain Med; 2021 May; 22(5):1205-1212. PubMed ID: 33585885 [TBL] [Abstract][Full Text] [Related]
36. Comparing rapid micro-induction and standard induction of buprenorphine/naloxone for treatment of opioid use disorder: protocol for an open-label, parallel-group, superiority, randomized controlled trial. Wong JSH; Nikoo M; Westenberg JN; Suen JG; Wong JYC; Krausz RM; Schütz CG; Vogel M; Sidhu JA; Moe J; Arishenkoff S; Griesdale D; Mathew N; Azar P Addict Sci Clin Pract; 2021 Feb; 16(1):11. PubMed ID: 33579359 [TBL] [Abstract][Full Text] [Related]
37. The SUMMIT trial: a field comparison of buprenorphine versus methadone maintenance treatment. Pinto H; Maskrey V; Swift L; Rumball D; Wagle A; Holland R J Subst Abuse Treat; 2010 Dec; 39(4):340-52. PubMed ID: 20817384 [TBL] [Abstract][Full Text] [Related]
39. A pilot study about the feasibility and cost-effectiveness of electronic compliance monitoring in substitution treatment with buprenorphine-naloxone combination. Tacke U; Uosukainen H; Kananen M; Kontra K; Pentikänen H J Opioid Manag; 2009; 5(6):321-9. PubMed ID: 20073406 [TBL] [Abstract][Full Text] [Related]